Becton, Dickinson and (BDX) closed at $191.55 on Oct 16, 2026, down 1.1% on the day. The stock is up 5.6% over the past month, up 24.0% over three months, up 25.5% year to date and up 30.5% over the past year. It trades 2.3% below its 52-week high of $195.99 and 50.1% above its 52-week low of $127.59. The close sits above its 50-day moving average ($183.39) and above its 200-day moving average ($163.94).
NextPick tracks BDX in its Medical Devices basket alongside ABT, ISRG, MDT, SYK and BSX. As of Oct 16, 2026, the basket's money-flow score is 15 (weak inflow), and the basket is up 4.5% over five sessions. Over the past month BDX ranks 4th of 13 basket members by price change.
Yes — the Oct 16, 2026 close of $191.55 is 16.8% above the 200-day average of $163.94.
BDX closed 2.3% below its 52-week high of $195.99.
NextPick groups BDX with ABT, ISRG, MDT, SYK and BSX in its Medical Devices basket.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of haza
